Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV): final report
- Author(s):
- Eastern Research Group, Inc., author.
- Contributor(s):
- Jessup, Amber, editor Scanlon, James V., editor Regier, Jerry, editor United States. Department of Health and Human Services. Office of the Assistant Secretary for Planning and Evaluation, issuing body.
- Publication:
- Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, 2007
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Immunoglobulins, Intravenous -- economics Immunoglobulins, Intravenous -- therapeutic use Medicare United States
- Abstract:
- Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S. Food and Drug Administration (FDA) has not classified IGIV as being in shortage, some patients' groups and physicians have been reporting problems to the U.S. Department of Health and Human Services (DHHS) regarding access under current Medicare reimbursement levels. Performed under contract to the DHHS Assistant Secretary of Planning and Evaluation (ASPE), the primary objective of this study is an examination of IGIV market dynamics and the potential health consequences of IGIV access problems.
- Copyright:
- The National Library of Medicine believes this item to be in the public domain (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101615447 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101615447